Enterprise Value
-70.53M
Cash
137.8M
Avg Qtr Burn
-11.31M
Short % of Float
1.92%
Insider Ownership
14.90%
Institutional Own.
43.77%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Azer-cel (PBCAR0191) (azercabtagene zapreleucel) Details Cancer, B-cell lymphoma, Diffuse large B cell lymphoma | Phase 1/2 Update | |
PBCAR19B (CD19 Allogeneic CAR-T) Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma | Phase 1 Update | |
PBCAR20A (targeting CD20) Details Non-Hodgkin lymphoma, Cancer, Chronic lymphocytic leukemia | Failed Discontinued | |
PBCAR269A (BCMA) Details Cancer, Multiple myeloma | Failed Discontinued |